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ECONOMIES OF SCALE IN INTENSIVE 
CARE UNITS
Rapoport J1, Edbrooke D2, Jacobs P3, Dean J2
1Mount Holyoke College, South Hadley, MA, USA; 2Royal
Hallamshire Hospital, Shefﬁeld, United Kingdom; 3Institute of
Health Economics, Edmonton, Alberta, Canada
OBJECTIVES: Understanding factors associated with the
average cost of providing critical care, particularly size of
unit, is important for many policy decisions. Study of pos-
sible economies of scale, i.e. decrease in average cost with
increased size of unit, has been limited due to a lack of
valid cost data collected on a uniform basis. This study
uses a cost database in which data from a group of 75
U.K. critical care units are held, collected using consistent
deﬁnitions. It estimates the extent of scale economies con-
trolling for other relevant critical care unit characteristics.
METHODS: Annual costs for 75 British critical care units
were obtained using a cost accounting system based 
on speciﬁc costs of resource inputs and prices. Cost 
categories included staff costs, consumables and clinical
support services. Multiple regressions using cost per
patient day as the dependent variable and log of unit size
(number of beds) as the major independent variable were
performed. Separate regressions were estimated for each
of the cost categories as well as for total costs. RESULTS:
Median unit size was 6 beds (IQR 4.9 to 8 beds). Median
total cost per patient day was £955 pounds (IQR £884
to £1105 pounds). A statistically signiﬁcant negative rela-
tionship between total cost per patient day and unit size
was found (p < .001, adjusted R-squared = .33). The size
coefﬁcient was also negative in the regression for each
cost component, and was statistically signiﬁcant in the
equations for staff and consumables costs. CONCLU-
SIONS: Average costs per patient day in British critical
care units decline with increased size of unit. The likeli-
hood of scale economies should be considered in facilities
planning, cost projection and budgeting, and economic
evaluation of policy proposals.
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OBJECTIVES: To analyse the factors inﬂuencing cost-
effectiveness of a health care intervention over time using
economic evaluations of epoetin alfa (EPO) as a case
study. When ﬁrst evaluated, EPO was not considered
cost-effective in the UK, but soon became widely used by
clinicians. METHODS: The analytical framework of a
study conducted in 1990 was used to revisit the cost-
effectiveness of EPO. Study variables were updated to
2000 values using a meta-analysis of the impact of EPO
on key cost drivers, supplemented by published unit cost
data and expert clinical opinion. Utilities for health states
associated with anaemia were taken from published
studies. The impact of the change in the value of each
variable on the cost-effectiveness ratio was assessed sep-
arately. RESULTS: After 10 years further experience of
the use of EPO the base case cost per QALY was reduced
from £171,810 to £17,067 (at 2000 prices), now falling
in the range considered acceptable by the National Insti-
tute for Clinical Excellence (NICE). The majority of the
reduction resulted from changes in the dosage and price
of EPO since 1990. Other factors making a sizeable con-
tribution were the revised QALY gains and the use of the
changed UK discount rate. Only one factor, the reduced
estimate of avoidance of transfusions, caused an increase
in the cost-effectiveness ratio since 1990. CONCLU-
SIONS: Cost-effectiveness can change over time with
improved data collection and changes in the utilisation
and cost of technologies. The existence of a body like
NICE in 1990 might have delayed the widespread adop-
tion of EPO in the UK, but the higher standards of clin-
ical and economic evidence demanded by such a body
might have expedited the appropriate pricing, dosage and
utilisation of the treatment. Whilst the factors inducing
the improved cost-effectiveness of EPO were identiﬁed in
the sensitivity analysis in 1990, the subsequent changes
could not easily be predicted at the time of the early 
evaluation.
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SHOULD THE EUROQOL DESCRIPTIVE SYSTEM
BE EXTENDED FROM THREE TO FIVE LEVELS? A
METHODOLOGICAL STRATEGY WITH AN
EMPIRICAL PILOT
Janssen MF, Bonsel GJ
Academic Medical Centre, Amsterdam, Netherlands
OBJECTIVES: The EuroQol-5D3L (= 3 levels) is the most
widely used health state instrument to calculate QALYs.
A major weakness, however, is lack of discrimination as
a result of only three levels within each domain. Apply-
ing QALYs in pharmacoeconomics may be hampered
when expected health gains are signiﬁcant, but small. We
established a formal approach to measure the gain of a 5
instead of 3 level EuroQol system, leaving the domains
unaltered. Construct validity, information gain (using a
quantiﬁcation system), and reliability were established.
METHODS: Forty-six patients with heterogeneous dis-
eases (n = 46) ﬁlled out the EuroQol questionnaire and a
visual analogue scale (VAS) twice, with a 1-day interval.
Patients were randomly assigned to the 3 or 5 level
version each occasion, thus creating four combinations of
EuroQol pairs between subjects (3-3, 3-5, 5-3 & 5-5).
The 5 level wording was discussed within the EuroQol
